MetaVia Inc. Market Cap ($8.30 Million)
Market Cap & Net Worth: MetaVia Inc. (MTVA)
MetaVia Inc. market cap. MetaVia Inc. (NASDAQ:MTVA) has a market capitalization of $8.30 Million ($8.30 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27407 globally and #5686 in its home market, demonstrating a 3.70% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MetaVia Inc.'s stock price $1.26 by its total outstanding shares 6588101 (6.59 Million). Also see cash efficiency ratio of MetaVia Inc. for how efficiently the company converts equity into cash flow.
MetaVia Inc. Market Cap History (2024–2026)
MetaVia Inc. market cap history from 2024 to 2026. Data shows change from $13.37 Million to $8.30 Million (-30.62% CAGR). Check MTVA stock price and chart for real-time trading data and today's change.
Index Memberships
MetaVia Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #773 of 976 |
Weight: MetaVia Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MetaVia Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MetaVia Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of MetaVia Inc. to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MTVA by Market Capitalization
Companies near MetaVia Inc. in the global market cap rankings as of November 4, 2026. Also see MTVA total assets for a full breakdown of the balance sheet.
Key companies related to MetaVia Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of MetaVia Inc. (2024–2026)
Market capitalization of MetaVia Inc. from 2024 to today. Between 2024 and today, MetaVia Inc.'s market cap moved from $13.37 Million to $ 8.30 Million, with a yearly change of -30.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $8.30 Million | -85.04% |
| 2025 | $55.47 Million | +314.78% |
| 2024 | $13.37 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of MetaVia Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.30 Million USD |
| MoneyControl | $8.30 Million USD |
| MarketWatch | $8.30 Million USD |
| marketcap.company | $8.30 Million USD |
| Reuters | $8.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as … Read more